From 1 January 1997 through 31 December 2000, 2,047 bloodstream infections (BSIs) due to Candida spp. were reported from hospitals in the United States, Canada, Latin America, and Europe participating in the SENTRY Antifungal Surveillance Program. Among individuals in four age groups (< or =1, 2 to 15, 16 to 64, and > or =65 years) @entity5132 was the most common species, causing 60, 55, 55, and 50% of infections, respectively. @entity7408 caused 17 to 23% of BSIs in those ages 16 to 64 and > or = 65 years, whereas it caused only 3% of BSIs in the individuals in the two younger age groups (P < 0.001). @entity7409 (which caused 21 to 24% of BSIs) and @entity9841 (which caused 7 to 10% of BSIs) were more common than @entity7408 in individuals ages < or =1 year and 2 to 15 years. Isolates of Candida spp. showed a trend of decreasing susceptibility to @entity2380 , @entity2059 , and @entity2379 with increasing @entity1 age (P < or = 0.01). None of the @entity7408 isolates from individuals < or =1 year old were resistant to @entity2380 , whereas they made up 5 to 9% of isolates from individuals ages 16 to 64 and > or =65 years. Isolates of @entity9841 from @entity1 < or =1 year old were more susceptible to @entity4895 (MIC at which 90% of isolates are inhibited [MIC(90)], 0.5 microg/ml; 0% resistant isolates) than those from @entity1 > or =65 years old (MIC(90), 32 microg/ml; 11% resistant isolates). The investigational triazoles @entity7143 , @entity32484 , and @entity5074 were all highly active against all species of Candida from individuals in all age groups. These data demonstrate differences in the species distributions of pathogens and differences in antifungal resistance among isolates from individuals in the pediatric and adult age groups. Ongoing surveillance will enhance efforts to limit the extent of antifungal resistance in individuals in various age groups.

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult XXXX with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

@entity9841 :: ('5482', 'Species') :: ['C. tropicalis'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B'] @entity2380 :: ('MESH:D015725', 'Chemical') :: ['fluconazole'] @entity7408 :: ('5478', 'Species') :: ['C. glabrata'] @entity4895 :: ('MESH:D005437', 'Chemical') :: ['flucytosine'] @entity7409 :: ('5480', 'Species') :: ['C. parapsilosis'] @entity5132 :: ('5476', 'Species') :: ['Candida albicans'] @entity32484 :: ('MESH:C104066', 'Chemical') :: ['ravuconazole'] @entity5074 :: ('MESH:C102790', 'Chemical') :: ['voriconazole'] @entity7143 :: ('MESH:C101425', 'Chemical') :: ['posaconazole'] @entity2059 :: ('MESH:D017964', 'Chemical') :: ['itraconazole']
@entity1 :: (9606,Species) :: ['patients']
